Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
740,884

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

RTI Surgical Gains From HealthPartners' Nod for SI Surgery

RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.

Medtronic's Deal With Nutrino Health to Boost Diabetes Arm

Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.

Medtronic Gets Health Canada License for Visualase System

Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.

Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified

Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.

Intuitive Surgical (ISRG) Gains As Market Dips: What You Should Know

Intuitive Surgical (ISRG) closed at $485.24 in the latest trading session, marking a +0.53% move from the prior day.

Intuitive Surgical (ISRG) Down 0.7% Since Last Earnings Report: Can It Rebound?

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Is (ISRG) Outperforming Other Medical Stocks This Year?

Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know

Intuitive Surgical (ISRG) closed at $498.64 in the latest trading session, marking a -0.95% move from the prior day.

GNC Holdings (GNC) Q3 Earnings Miss on Soft U.S. Retail

GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.

Looking for a Growth Stock? Why It is Time to Focus on Intuitive Surgical (ISRG)

Intuitive Surgical (ISRG) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y

Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.

OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates

OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.

Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2

Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.

athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y

athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.

DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View

Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.

Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.

Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?

Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.

BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat

A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.

Wright Medical (WMGI) Reports Q3 Loss, Raises '18 Guidance

Growth in the upper and the lower extremity segments drives Wright Medical's (WMGI) Q3 results

Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up

Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.

Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates

We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.

Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know

Intuitive Surgical (ISRG) closed at $540.02 in the latest trading session, marking a -1.04% move from the prior day.

DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down

DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.